The Israeli stock market is a good test for the old saying that war is good for the economy. Is it investing maxim or enduring myth?» Read More
March 13- Generic injectable drugs maker Sagent Pharmaceuticals Inc is looking to shore up its portfolio with deals worth up to $500 million, as rampant manufacturing issues and quality concerns push consolidation in the industry.
Pfizer said a court had invalidated a key patent behind its blockbuster Celebrex drug, and plans to appeal the judgement.
March 11- Teva Pharmaceutical Industries Ltd agreed to pay $27.6 million to settle charges that it paid kickbacks to a Chicago psychiatrist to induce him to prescribe an anti-schizophrenia drug to patients, resulting in more than 100,000 false Medicaid and Medicare claims.
Cramer honestly believes that regular investors can outperform the broad market every day, including today, simply by following this strategy.
The "Fast Money" traders share their final trades of the day.
*Teva, Ranbaxy to pay $150,000 each to settle with New York State. Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition.
Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition. Teva and Ranbaxy will pay the New York state $300,000 and have agreed to refrain from similar agreements in the future.
Some of Tuesday's midday movers:
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
Some of Thursday's midday movers:
Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.
Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.
Some of Wednesday's midday movers:
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Take a look at some of Friday's midday movers: Twitter, Textron, Sprint
Some of the names on the move ahead of the open.
Jim Cramer often advocates viewing a sell-off as opportunity. Often, but not always.
Take a look at some of Wednesday's midday movers:
Take a look at some of Monday's midday movers:
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.